• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • UK / Ireland

Lion to make 5x money on Weetabix

  • Kimberly Romaine
  • 03 May 2012
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Lion Capital has sold 60% of UK cereal business Weetabix to Chinese food group Bright Food, in a deal that values the company at £1.2bn.

Once the remaining stake has been sold to Bright Food, expected in two to three years, Lion should make near 5x its money, according to a source close to the deal.

The asset has been on the block since the middle of last year, and the sale comes after Weetabix restructured around £900m of its debts. It required 80% acceptance to extend its loans but managed to get nearer 90% as a result of paying down some debt with cash and sweetening the deal with margin uplift.

Lion is said to have already generated a 3x return on its initial investment through several dividend payments; when the business fully is exited this should rise to nearly 5x.

At the time of the take-private, Weetabix reported turnover of £361.6m and pre-tax profits of £44.4m. By 2010, the business reported a gross profit of £20.4m from revenues of £449m. Weetabix employed 1,700 people at the time of the initial buyout and 1,800 today.

Previous funding
Lion (then Hicks Muse Tate and Furst) took Weetabix private in 2004 in a deal that valued the business at £642m. The firm paid £268.75 per ordinary share and £53.75 for each ordinary A share.

Company
Weetabix is a Kettering-based breakfast cereal manufacturer with brands that include Alpen, Weetabix, Weetos and Ready Brek. It exports to 80 countries worldwide and employs 1,800 people. The company was founded in 1932 and has been run by the George family since before World War II. The largest single shareholder prior to Lion's acquisition in 2002 was Gardner Russo, a US wealth management company which owned a 14.5% stake. The George family owned a combined 20% of the business.

Advisers
Equity – Weil Gotshal & Manges (Legal).
Acquirer – Rothschild (Corporate finance); Linklaters (Legal).

Weetabix

  • DEAL:

    Trade sale

  • VALUE:

    £1.2bn

  • LOCATION:

    Kettering, UK

  • SECTOR:

    Food products

  • FOUNDED:

    1932

  • TURNOVER:

    £449m (2010)

  • EBITDA:

    £20.4m (2010)

  • STAFF:

    1,800

  • VENDOR:

    Lion Capital

  • RETURNS:

    c5x (when fully exited)

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • UK / Ireland
  • Exits
  • Consumer
  • United Kingdom
  • Lion Capital (formerly Hicks Muse)
  • Linklaters
  • Weil Gotshal & Manges
  • Trade sale

More on UK / Ireland

Fund closes in US dollars
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • Funds
  • 05 September 2023
Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
Public sector software
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013